Through Numinus Bioscience, Numinus has a Health Canada cannabis testing license that allows the company to test and analyze cannabis products from licensed producers. In addition, through a wholly-owned subsidiary Salvation Botanicals, Numinus is a late-stage applicant to receive a Health Canada standard processing license to produce cannabis products.
Additional Information:
Video Transcript:
I’m Fiona Forbes for Investmentpitch Media
Numinus Wellness, a Vancouver-based health care company, is one of the latest new listings on the TSX Venture Exchange, trading under the symbol “NUMI”, following its RTO with ROJO Resources.
Through Numinus Bioscience, Numinus has a Health Canada cannabis testing license that allows the company to test and analyze cannabis products from licensed producers.
In addition, through a wholly-owned subsidiary Salvation Botanicals, Numinus is a late-stage applicant to receive a Health Canada standard processing license to produce cannabis products.
Payton Nyquvest, CEO, stated: "This is an exciting day for all of us at Numinus. We are on a mission
to help address the universal desire to heal and be well. We are looking for like-minded investors
who share our belief that new approaches and new ways of thinking are needed to supplement existing options. We are excited about the future of psychedelics and our focus will solely be on its therapeutic use. Psychedelics will move forward in a therapeutic and research context, where the application of these substances will only happen in safe, controlled treatment environments. Numinus has these pieces in place today."
The company has appointed Dr. Evan Wood, MD, PhD as Chief Medical Officer.
Over a 20-year career, Dr. Wood has gained international recognition as a leading researcher into addiction, most recently as the Executive Director of the British Columbia Centre on Substance Use (www.bccsu.ca), a leading research organization into the treatment of substance use and addiction.
Dr. Evan Wood, stated: "I share the Numinus position that the societal costs of mental illness, addiction, trauma and unmet human potential are much too high. My work and the work of others in the field indicate the value of continuing to explore the use of psychedelic substances in safe, controlled therapeutic environments to address these issues, and I look forward to positioning Numinus as a leader in this emerging area of treatment."
Numinus has a dealer's licence which allows the company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline and is seeking to expand the licence to include activities such as import/export, testing and R&D.
The expanded license will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through research projects, product development, and the supply and distribution of these substances.
Numinus also operates a stand-alone centre offering patients integrative health solutions to help heal, connect and grow.
The first wellness centre, located in Vancouver, includes six treatment rooms, event/studio space, 15+ therapeutic team including doctors of medicine and naturopathy, and registered nurses.
Psychedelics will be part of this offering but will only be available for treatment once approved by
regulators and governing bodies, a process Numinus is helping to support.
The company is well financed, having raised $6.8 million between December 2019 and March 2020.
The shares are trading at $0.98.
For more information, please visit the company’s website www.numinus.ca, contact Payton Nyquvest, CEO, at invest@numinus.ca.
I’m Fiona Forbes for Investmentpitch Media
